Cell Cycle Effects and Increased Adduct Formation by Temozolomide Enhance the Effect of Cytotoxic and Targeted Agents in Lung Cancer Cell Lines

REFERENCES

• Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 1997; 23 (1): 35–61.
   PubMed Web of Science ®Google Scholar
• Denny BJ, Wheelhouse RT, Stevens MF, Tsang LL, Slack JA. NMR and molecular modeling investigation of the mecha-nism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry 1994; 33 (31): 9045–9051.
   PubMed Web of Science ®Google Scholar
• D'Atri S, Tentori L, Lacal PM, Graziani G, Pagani E, Ben-incasa E, et al. Involvement of the mismatch repair system in temozolomide-induced apoptosis. Mol Pharmacol 1998; 54 (2): 334–341.
   PubMed Web of Science ®Google Scholar
• Marchesi F, Turriziani M, Tortorelli G, Awisati G, Torino F, De Vecchis L. Triazene compounds: mechanism of action and related DNA repair systems. Pharmacol Res 2007; 56 (4): 275–287.
   PubMed Web of Science ®Google Scholar
• Casorelli I, Russo MT, Bignami M. Role of mismatch repair and MGMT in response to anticancer therapies. Anticancer Agents Med Chem 2008; 8 (4): 368–380.
   PubMed Web of Science ®Google Scholar
• Payne MJ, Pratap SE, Middleton MR. Temozolomide in the treatment of solid tumours: current results and rationale for dos-ing/scheduling. Crit Rev Oncol Hematol 2005; 53 (3): 241–252.
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and ad-juvant temozolomide for glioblastoma. N Engl J Med 2005; 352 (10): 987–996.
   PubMed Web of Science ®Google Scholar
• Gerson SL. MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 2004; 4 (4): 296–307.
   PubMed Web of Science ®Google Scholar
• Esteller M, Herman JG. Generating mutations but provid-ing chemosensitivity: the role of 0(6)-methylguanine DNA methyltransferase in human cancer. Oncogene 2004; 23 (1): 1–8.
   PubMed Web of Science ®Google Scholar
• Hegi ME, Diserens AC, Godard S, Dietrich PY, Regli L, Ostermann S, et al. Clinical trial substantiates the predictive value of 0-6-methylguanine-DNA methyltransf erase promoter methy-lation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004; 10 (6): 1871–1874.
   PubMed Web of Science ®Google Scholar
• Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temo-zolomide in glioblastoma. N Engl J Med 2005; 352 (10): 997–1003.
   PubMed Web of Science ®Google Scholar
• Pegg AE. Repair of 0(6)-alkylguanine by alkyltransf erases. Mutat Res 2000; 462 (2-3): 83–100.
   PubMed Web of Science ®Google Scholar
• Gerson SL, Zborowska E, Norton K, Gordon NH, Willson JK. Synergistic efficacy of 06-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in a human colon cancer xenograft completely resistant to BCNU alone. Biochem Phar-macol 1993; 45 (2): 483–491.
   PubMed Web of Science ®Google Scholar
• Quinn JA, Desjardins A, Weingart J, Brem H, Dolan ME, Delaney SM, et al. Phase I trial of temozolomide plus 06-ben-zylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol 2005; 23 (28): 7178–7187.
   PubMed Web of Science ®Google Scholar
• Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG. Inactivation of the DNA repair gene 06-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 1999; 59 (4): 793–797.
   PubMed Web of Science ®Google Scholar
• Keepers YP, Pizao PE, Peters GJ, van Ark-Otte J, Wino-grad B, Pinedo HM. Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing. Eur J Cancer 1991; 27 (7): 897–900.
   PubMed Web of Science ®Google Scholar
• Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22 27–55.
   PubMedGoogle Scholar
• Chou TC, Motzer RJ, Tong Y, Bosl GJ. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a ra-tional approach to clinical protocol design. J Natl Cancer Inst 1994; 86 (20): 1517–1524.
   PubMed Web of Science ®Google Scholar
• Peters GJ, van der Wilt CL, van Moorsel CJ, Kroep JR, Bergman AM, Ackland SP. Basis for effective combination can-cer chemotherapy with antimetabolites. Pharmacol Ther 2000; 87 (2-3): 227–253.
   PubMed Web of Science ®Google Scholar
• Temmink OH, Hoebe EK, Van der Born K, Ackland SP, Fukushima M, Peters GJ. Mechanism of trifluorothymidine po-tentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells. Br J Cancer 2007; 96 (2): 231–240.
   PubMed Web of Science ®Google Scholar
• Lind GE, Thorstensen L, Lovig T, Meling GI, Hamelin R, Rognum TO, et al. A CpG island hypermethylation profile of pri-mary colorectal carcinomas and colon cancer cell lines. Mol Can-cer 2004; 3 (1):
   PubMedGoogle Scholar
• Crain PF. Preparation and enzymatic hydrolysis of DNA and RNA for mass spectrometry. Methods Enzymol 1990; 193 782–790.
   PubMed Web of Science ®Google Scholar
• Yang Y, Nikolic D, Swanson SM, van Breemen RB. Quan-titative determination of N7-methyldeoxyguanosine and O6-methyldeoxyguanosine in DNA by LC-UV-MS-MS. Anal Chem 2002; 74 (20): 5376–5382.
   PubMed Web of Science ®Google Scholar
• Song L, James SR, Kazim L, Karpf AR. Specific method for the determination of genomic DNA methylation by liquid chromatography-electrospray ionization tandem mass spectrom-etry. Anal Chem 2005; 77 (2): 504–510.
   PubMed Web of Science ®Google Scholar
• Baker SD, Wirth M, Statkevich P, Reidenberg P, Alton K, Sartorius SE, et al. Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. Clin Cancer Res 1999; 5 (2): 309–317.
   PubMed Web of Science ®Google Scholar
• Tolis C, Peters GJ, Ferreira CG, Pinedo HM, Giaccone G. Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines. Eur J Cancer 1999; 35 (5): 796–807.
   PubMed Web of Science ®Google Scholar
• Kroep JR, Giaccone G, Tolis C, Voorn DA, Loves WJ, Groeningen CJ, et al. Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotox-icity in non-small-cell lung cancer cell lines. Br J Cancer 2000; 83 (8): 1069–76.
   PubMed Web of Science ®Google Scholar
• Kim ES, Kies MS, Fossella FV, Glisson BS, Zaknoen S, Statkevich P, et al. Phase II study of the farnesyltransferase in-hibitor lonafarnib with paclitaxel in patients with taxane-refrac-tory/resistant nonsmall cell lung carcinoma. Cancer 2005; 104 (3): 561–569.
   PubMed Web of Science ®Google Scholar
• Morgillo F, Lee HY. Lonafarnib in cancer therapy. Expert Opin Investig Drugs 2006; 15 (6): 709–719.
   PubMed Web of Science ®Google Scholar
• Hirose Y, Berger MS, Pieper RO. Abrogation of the Chkl-mediated G(2) checkpoint pathway potentiates temozolo-mide-induced toxicity in a p53-independent manner in human glioblastoma cells. Cancer Res 2001; 61 (15): 5843–5849.
   PubMed Web of Science ®Google Scholar
• Hirose Y, Katayama M, Stokoe D, Haas-Kogan DA, Berger MS, Pieper RO. The p38 mitogen-activated protein ki-nase pathway links the DNA mismatch repair system to the G2 checkpoint and to resistance to chemotherapeutic DNA-methy-lating agents. Mol Cell Biol 2003; 23 (22): 8306–8315.
   PubMed Web of Science ®Google Scholar
• Ikediobi ON, Davies H, Bignell G, Edkins S, Stevens C, O'Meara S, et al. Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol Cancer Ther 2006; 5 (11): 2606–2612.
   PubMed Web of Science ®Google Scholar
• Naumann SC, Roos WP, Jost E, Belohlavek C, Lennerz V, Schmidt CW, et al. Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53. Br J Cancer 2009; 100 (2): 322–333.
   PubMed Web of Science ®Google Scholar
• Roos WP, Nikolova T, Quiros S, Naumann SC, Kiedron O, 7d7ienicka MZ, et al. Brca2/Xrcc2 dependent HR, but not NHEJ, is required for protection against 0(6)-methylguanine trig-gered apoptosis, DSBs and chromosomal aberrations by a process leading to SCEs. DNA Repair (Amst) 2009; 8 (1): 72-86.
   Google Scholar
• Wang D, Lippard SJ. Cellular processing of platinum an-ticancer drugs. Nat Rev Drug Discov 2005; 4 (4): 307–320.
   PubMed Web of Science ®Google Scholar
• Ebert BL, Niemierko E, Shaffer K, Salgia R. Use of temo-zolomide with other cytotoxic chemotherapy in the treatment of patients with recurrent brain metastases from lung cancer. On-cologist 2003; 8 (1): 69–75.
   PubMed Web of Science ®Google Scholar
• Dziadziuszko R, Ardizzoni A, Postmus PE, Smit EF, Price A, Debruyne C, et al. Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases. a phase II study of the EORTC Lung Cancer Group (08965). Eur J Cancer 2003; 39 (9): 1271-1276.
   Google Scholar
• Addeo R, De Rosa C., Faiola V, Leo L, Cennamo G, Mon-tella L, et al. Phase 2 trial of temozolomide using protracted low-dose and whole-brain radiotherapy for nonsmall cell lung cancer and breast cancer patients with brain metastases. Cancer 2008; 113 (9): 2524–2531.
   PubMed Web of Science ®Google Scholar
• Azzabi A, Hughes AN, Calvert PM, Plummer ER, Todd R, Griffin MJ, et al. Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigations. Br J Cancer 2005; 92 (6): 1006–1012.
   PubMed Web of Science ®Google Scholar
• Bafaloukos D, Gogas H, Georgoulias V, Briassoulis E, Fountzilas G, Samantas E, et al. Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group. J Clin Oncol 2002; 20 (2): 420–425.
   PubMed Web of Science ®Google Scholar
• Tamaskar I, Mekhail T, Dreicer R, Olencki T, Roman S, Elson P, et al. Phase I trial of weekly docetaxel and daily temo-zolomide in patients with metastatic disease. Invest New Drugs 2008; 26 (6): 553–559.
   PubMed Web of Science ®Google Scholar
• Patel VJ, Elion GB, Houghton PJ, Keir S, Pegg AE, John-son SP, et al. Schedule-dependent activity of temozolomide plus CPT-11 against a human central nervous system tumor-derived xenograft. Clin Cancer Res 2000; 6 (10): 4154–4157.
   PubMed Web of Science ®Google Scholar
• Choong NW, Mauer AM, Hoffman PC, Rudin CM, Wine-garden JD, III, Villano JL, et al. Phase II trial of temozolomide and irinotecan as second-line treatment for advanced non-small cell lung cancer. J Thorac Oncol 2006; 1 (3): 245–251.
   PubMed Web of Science ®Google Scholar
• Dodds HM, Haaz MC, Riou JF, Robert J, Rivory LP. Iden-tification of a new metabolite of CPT-11 (irinotecan): pharma-cological properties and activation to SN-38. J Pharmacol Exp Ther 1998; 286 (1): 578–583.
   PubMed Web of Science ®Google Scholar
• Hande KR. Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer 1998; 34 (10): 1514–1521.
   PubMed Web of Science ®Google Scholar
• Jordan MA, Wilson L. Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr Opin Cell Biol 1998; 10 (1): 123–130.
   PubMed Web of Science ®Google Scholar
• Faivre S, Chan D, Salinas R, Woynarowska B, Woy-narowski JM. DNA strand breaks and apoptosis induced by ox-aliplatin in cancer cells. Biochem Pharmacol 2003; 66 (2): 225–237.
   PubMed Web of Science ®Google Scholar
• Appels NM, Beijnen JH, Schellens JH. Development of famesyl transferase inhibitors: a review. Oncologist 2005; 10 (8): 565–578.
   PubMed Web of Science ®Google Scholar
• Plunkett W, Huang P, Searcy CE, Gandhi V. Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol 1996; 23 (5 Suppl 10): 3-15.
   Google Scholar
• Bergman AM, Eijk PP, Ruiz van Haperen V, Smid K, Veerman G, Hubeek I, et al. In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant. Cancer Res 2005; 65 (20): 9510-9516.
   PubMed Web of Science ®Google Scholar